LatestGilead's Oral Treatment Eliminates IBS Symptoms in Mid-Stage Study
Health

Opinion: Medical Aid in Dying for Psychiatric Conditions—A Mother's Story

Torie Bosch
Opinion: Medical Aid in Dying for Psychiatric Conditions—A Mother's Story
SchizophreniaBipolar DisorderGeneralized Anxiety DisorderMajor Depressive Disorder
Summary

Torie Bosch shares a personal perspective on medical aid in dying, reflecting on her mother's suicide and arguing that severe, treatment-resistant mental illness can be as terminal as physical disease. The essay examines the debate around expanding assisted suicide eligibility to include psychiatric conditions in jurisdictions where medical aid in dying is permitted. This discussion raises important questions about end-of-life options, mental health treatment limitations, and ethical considerations for patients with severe, persistent mental illness. The piece contributes to ongoing conversations about mental health policy and compassionate care options.

Stat News

Originally published on

STAT News

By Torie Bosch

Read full article(opens in new tab)

Fetched: October 19, 2026 at 10:00 AM

More news you might be interested in

View all
Gilead's Oral Treatment Eliminates IBS Symptoms in Mid-Stage Study
Health
Irritable Bowel Syndrome

Gilead's Oral Treatment Eliminates IBS Symptoms in Mid-Stage Study

Gilead Sciences announced positive mid-stage study results for an oral medication that successfully eliminated symptoms in patients with irritable bowel syndrome (IBS). The drug, which targets inflammatory mechanisms in the gastrointestinal tract, represents a potential new treatment option for this common condition affecting millions worldwide. IBS causes chronic abdominal pain, bloating, diarrhea, and constipation, significantly impacting quality of life. These promising results could advance the medication toward late-stage trials and potential FDA approval. The findings offer hope for IBS patients seeking more effective symptom management options.

2 hours ago
STAT News
No Surprises Act's Nonprofit Arbitrators Accumulating Wealth While Protecting Patients
Health

No Surprises Act's Nonprofit Arbitrators Accumulating Wealth While Protecting Patients

A STAT investigation reveals that nonprofit organizations serving as arbitrators under the No Surprises Act are accumulating substantial financial gains while adjudicating disputes over surprise medical bills. These organizations, designed to protect patients from unexpected out-of-network charges, have become highly profitable entities operating with minimal oversight. The arbitration program, which was established to shield healthcare consumers from financial hardship due to unexpected medical costs, now raises questions about conflicts of interest and accountability. This finding highlights potential systemic issues in how patient protection mechanisms are being monetized by intermediary organizations.

2 hours ago
STAT News
Opinion: Measles Resurgence Becomes Political Issue for Republicans
Health

Opinion: Measles Resurgence Becomes Political Issue for Republicans

Physician leaders and former Republican representatives Larry Buchson and Michael Burgess argue that vaccine hesitancy is becoming a significant political liability for GOP candidates. The resurgence of measles, a highly contagious preventable disease, has prompted physicians to warn that voter silence on vaccine policy could cost Republicans support among healthcare-conscious constituents. With measles cases rising in communities with low vaccination rates, medical professionals emphasize that clear, science-based vaccine advocacy is essential for public health. The commentary highlights how vaccine confidence has become a critical electoral issue affecting voting decisions across party lines.

2 hours ago
STAT News
Can Isomorphic Labs Revolutionize Drug Development With AI Technology?
Health

Can Isomorphic Labs Revolutionize Drug Development With AI Technology?

Isomorphic Labs aims to transform pharmaceutical manufacturing by leveraging advanced technology to accelerate medicine development. The company's approach seeks to address a critical challenge in healthcare: bringing new treatments to patients faster and more efficiently. Success could reshape how drugs are discovered and manufactured across the industry. The question remains whether their innovative platform can deliver on ambitious promises and overcome existing barriers in drug development timelines and costs.

2 hours ago
STAT News